"Inconsistencies" lead to temporary halt
YUMA, Ariz. (KYMA, KECY) - The maker of a popular over-the-counter headache medication has put a temporary pause on production.
GlaxoSmithKline says it stopped making Excedrin Extra Strength and Excedrin migraine in both caplets and gel-tabs after discovering "inconsistencies in how we transfer and weigh ingredients."
"Patient safety and product quality are our utmost priorities at GSK. Through routine quality control and assurance measures, we discovered inconsistencies in how we transfer and weigh ingredients for Excedrin Extra Strength Caplets and Geltabs and Excedrin Migraine Caplets and Geltabs. Based on the available data, GSK believes that the product does not pose a safety risk to consumers. However, as a precautionary measure, GSK Consumer Healthcare voluntarily implemented a temporary discontinuation of production and distribution. "GlaxoSmithKline statement on Excedrin products
The pharmaceutical company doesn't believe the medications pose any safety risk to consumers.
It says the pause in production is only precautionary. It plans to begin making the headache medications again in the near future.
"This is a short term issue for which we expect production to begin again shortly. In the meantime, other Excedrin products are available along with other pain-relieving drugs, but dosages may differ. Consumers should consult their pharmacist for the most suitable alternative product."GlaxoSmithKline statement on Excedrin products
Excedrine PM Headache and Excedrin Tension Headache are still available in stores.